EGA President Ms Gudbjorg Edda Eggertsdottir, speaking at the European Generic medicines Association’s (EGA’s) conferences in London, UK (11th EGA International Symposium on Biosimilar Medicines) and in Athens, Greece (19th EGA Annual Conference); stressed the importance of keeping generics and biosimilars manufacturers within Europe, thus ensuring that high quality manufacturing jobs and know-how remains in Europe. This would benefit society and patients and increase the competitiveness and innovative capacity of the pharmaceutical industry in Europe.
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilares
Novedades
- Canada approves pegfilgrastim biosimilar Armlupeg
- FDA approves fifth ustekinumab biosimilar Imuldosa
- EC approval for three ustekinumab biosimilar: Eksunbi, Fymskina, Otulfi
- FDA approves biosimilars: ustekinumab Otulfi and eculizumab Epysqli
Investigación
- Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
- Análisis del impacto presupuestario de la introducción de Rixathon en Chile para el linfoma no Hodgkin
- Biosimilars in inflammatory bowel disease: are we ready for multiple switches
- Resultados principales del programa de desarrollo clínico del biosimilar candidato AVT05 golimumab
General
- Biosimilar medicines on the Pharmaceutical Benefits Scheme in Australia
- La SBR emite consenso sobre intercambiabilidad de productos de referencia y biosimilares
- Un innovador acuerdo de compra directa permite reducir drásticamente los precios de los biosimilares de adalimumab
- Stelara biosimilar available at US$0 for Accredo patients
- MORE EDITORIAL SECTIONS
- Search
Comments (0)
Post your comment